摘要
目的分析食管癌组织程序性细胞死亡蛋白-1(PD-1)、PD-1的配体(PD-L1)表达对中晚期食管癌患者化疗近期疗效的影响,为中晚期食管癌的治疗提供参考。方法收集2014年1月至2016年1月期间在本院住院治疗的中晚期食管癌患者86例,所有患者均接受吉西他滨联合顺铂治疗,化疗前均行免疫组化法检测食管癌组织中PD-1、PD-L1表达量,对比PD-1、PD-L1阳性与PD-1、PD-L1阴性患者间在化疗后3个月时对化疗的敏感率。结果86例食管癌患者的癌组织标本PD-1阳性44例,PD-L1阳性43例,阳性率分别为51.2%、50.0%。PD-1阳性患者的化疗敏感率9.1%,明显低于PD-1阴性患者的26.2%(P<0.05),PD-L1阳性患者的化疗敏感率2.3%,明显低于PD-L1阴性患者的32.6%(P<0.05)。结论食管癌组织中阳性表达PD-1/PD-L1的患者对化疗的敏感率明显低于阴性表达PD-1/PD-L1者,这提示我们,对PD-1/PD-L1阳性的食管癌患者,通过阻断PD-1/PD-L1通路可能是更合适的治疗方案,应引起重视。
Objective To analyze the effect of the expression of programmed cell death protein-1(PD-1)and PD-L1 of esophageal cancer tissue on the short-term effect of chemotherapy in patients with advanced esophageal cancer,so as to provide a reference for the treatment of advanced esophageal cancer.Methods 86 patients with advanced esophageal cancer in our hospital from January 2014 to January 2016 were collected.All patients were treated with gemcitabine and cisplatin.Before chemotherapy,the expression of PD-1 and PD-L1 of esophageal cancer tissue were detected by immunohistochemistry.The sensitivity of PD-1 and PD-L1 positive patients to chemotherapy were compared with that of PD-1 and PD-L1 negative patients at 3 months after chemotherapy.Results Among 86 cases of esophageal cancer,there were 44 cases of positive PD-1 and 43 cases of positive PD-L1,the positive rates were respectively 51.2%and 50.0%.The sensitivity of PD-1 positive patients was 9.1%,which was significantly lower than 26.2%of PD-1 negative patients(P<0.05),and the sensitivity of PD-L1 positive patients was 2.3%,which was significantly lower than 32.6%of PD-L1 negative patients(P<0.05).Conclusion The sensitivity of PD-1/PD-L1 positive patients to chemotherapy is significantly lower than that of PD-1/PD-L1 negative patients,which suggests that blocking PD-1/PD-L1 pathway may be a more appropriate treatment method for PD-1/PD-L1 positive esophageal cancer patients.
作者
徐小玉
吴兵
韩海娥
Xu Xiaoyu;Wu Bing;Han Haie(Department of Oncology,Weihai Central Hospital,Weihai 264400,China)
出处
《国际医药卫生导报》
2020年第3期370-373,共4页
International Medicine and Health Guidance News
关键词
食管癌
程序性细胞死亡蛋白-1
化疗
免疫功能
淋巴细胞
Esophageal cancer
Programmed cell death protein-1
Chemotherapy
Immune function
Lymphocyte
